Dan represents biotech and pharmaceutical companies in all areas of patent counseling, including lifecycle management, patent portfolio development and restructuring, post-issuance proceedings, investment and transactional intellectual property due diligence and offensive and defensive patent strategy. He is a registered patent lawyer.

Dan has extensive experience in pharmaceutical lifecycle management, both for marketed pharmaceutical products and for products in late-stage clinical development that require additional patent term. Prior to joining Fenwick, Dan was responsible for worldwide prosecution of a second-generation patent family protecting the world's best-selling prescription pharmaceutical, including coordinating successful defense against 15 European opponents. For a venture-backed company repurposing a drug product that had earlier failed phase 3 clinical trials in a different indication, Dan designed a strategy for newly claiming the drug substance per se, including advice on new in vitro experiments, drafting, filing and prosecution of a new patent family, achieving allowance of Orange Book-listable claims shortly after acquisition of the company for $325 million upfront plus $120 million in contingent value rights.